Taikang Asset Management (HK)’s Vir Biotechnology VIR Stock Holding History

Taikang Asset Management (HK)’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-533,332	Closed	-$13.7M	–	74
2022 Q1	$13.7M	Hold	533,332	–	–	2.34%	12
2021 Q4	$22.3M	Hold	533,332	–	–	4.45%	5
2021 Q3	$23.2M	Hold	533,332	–	–	4.71%	5
2021 Q2	$25.2M	Hold	533,332	–	–	3.89%	6
2021 Q1	$27.3M	Sell	533,332 -88,889	-14%	-$4.79M	5.16%	5
2020 Q4	$16.7M	Hold	622,221	–	–	2.46%	10
2020 Q3	$21.4M	Hold	622,221	–	–	3.3%	8
2020 Q2	$25.5M	Buy	+622,221	New	+$20.9M	4.54%	6

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

Taikang Asset Management (HK)'s VIR Position: Q2 2022 in Review

Taikang Asset Management (HK) sold out of Vir Biotechnology (VIR) in Q2 2022, closing a stake of 533,332 shares — an estimated $13.7M sold.

Taikang Asset Management (HK) first reported a position in VIR in Q2 2020 and held it in 8 quarters. The position peaked at $27.3M in Q1 2021. 212 funds tracked by Wall St. Rank hold VIR as of Q2 2022.

Taikang Asset Management (HK) reported no remaining Vir Biotechnology position as of Q2 2022 after selling out during the quarter.
Taikang Asset Management (HK) sold 533,332 Vir Biotechnology shares in Q2 2022, an estimated $13.7M.
Taikang Asset Management (HK) first reported a position in Vir Biotechnology in Q2 2020 and held it in 8 quarters.
Taikang Asset Management (HK)'s Vir Biotechnology position peaked at $27.3M in Q1 2021.
212 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2022.

Based on Taikang Asset Management (HK)'s 13F filing for Q2 2022, filed 9 Aug 2022.